Investing.com - ABVC Biopharma (NASDAQ: ABVC) reported first quarter EPS of $-0.06, worse than the analyst estimate of $-0.05. Revenue for the quarter came in at $128.3K versus...
Investing.com - ABVC Biopharma (NASDAQ: ABVC) reported fourth quarter EPS of $0.17, $0.32 better than the analyst estimate of $-0.15. Revenue for the quarter came in at $589.78K...
Investing.com - ABVC Biopharma reported on Monday third quarter earnings that beat analysts' forecasts and revenue that topped expectations. ABVC Biopharma announced earnings per...
Investing.com – U.S. stocks were lower after the close on Friday, as losses in the Technology, Consumer Services and Financials sectors led shares lower. At the close in NYSE, the...
Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Basic Materials, Technology and Healthcare sectors led shares higher. At the close in NYSE, the...
Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Consumer Goods, Oil & Gas and Basic Materials sectors led shares higher. At the close in NYSE,...
ABVC BioPharma, Inc. (ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today...
ABVC BioPharma, Inc. (ABVC) announced today that it had entered into a Cooperation Agreement to exchange a 20% ownership stake in real estate property of Zhonghui United Technology...
ABVC BioPharma, Inc. (ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, announced...
ABVC BioPharma, Inc. (ABVC), a clinical-stage biopharmaceutical company specializing in therapeutic solutions in oncology/hematology, neurology, and ophthalmology, announced that...